Granting of options over ordinary shares

EDX Medical Group PLC

21 April 2026

 

21 April 2026

EDX Medical Group plc · EDX

AQSE: EDX

("EDX Medical" or the "Company")

Granting of options over ordinary shares

CAMBRIDGE, UK: EDX Medical Group plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, today announces that it has granted options over ordinary shares in the Company to directors and other members of senior management. 

The intention to grant options over ordinary shares in the Company was announced to the market on April 13, 2026, as part of the announcement on the proposed application for admission to trading on AIM and proposed withdrawal of the Company's ordinary shares from AQSE. The details of the proposed share options were contained within that announcement. 

Prior to the announcement on April 13, 2026, Mr Martin Walton, Deputy Chairman of the Company, already held options over 3,750,000 ordinary shares in the Company. 

The announcement of April 13, 2026, stated the intention for Mr Walton to be granted options over a further 4,214,286 ordinary shares in the Company under the EDX Medical Group plc Non-Enterprise Management Incentive Plan.  

The Board has agreed that Mr Walton's previous option over 3,750,000 ordinary shares in the Company should be cancelled and 're-awarded' under the EDX Medical Group plc Non-Enterprise Management Incentive Plan. This means that Mr Walton now holds options over 7,964,286 ordinary shares in the Company under the EDX Medical Group Plc Non-Enterprise Management Incentive Plan. In addition, Mr Walton holds options over 1,785,714 ordinary shares in the Company under the EDX Medical Group plc Enterprise Management Incentive Plan. Mr Walton's total options over ordinary shares in the Company now stands at 9,750,000. 

The directors of the Company accept responsibility for the contents of this announcement. 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Martin Walton
2	Reason for the notification
a)	Position/status	Board Director / Deputy Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	EDX Medical Group plc
b)	LEI	213800BZVJZTMCZ6DJ63
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of  £0.01 each
	Identification code	ISIN: GB00BNDMJS47
b)	Nature of the transaction	Granting of options over ordinary shares under (i) the EDX Medical Group plc Non-Enterprise Management Incentive Plan and (ii) the EDX Medical Group plc Enterprise Management Incentive Plan
c)	Price(s) and volume(s)
			Price	Volume
			(i)    NIL	7,964,286
			(ii)   NIL	1,785,714
d)	Aggregated information
	- Aggregated volume	9,750,000
	- Price	NIL
e)	Date of the transaction	2026-04-17
f)	Place of the transaction	XOFF - Outside of a Trading Venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shafia Zahoor
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	EDX Medical Group plc
b)	LEI	213800BZVJZTMCZ6DJ63
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of  £0.01 each
	Identification code	ISIN: GB00BNDMJS47
b)	Nature of the transaction	Granting of options over ordinary shares under (i) the EDX Medical Group plc Non-Enterprise Management Incentive Plan and (ii) the EDX Medical Group plc Enterprise Management Incentive Plan
c)	Price(s) and volume(s)
			Price	Volume
			(i)    Nil	43,214
			(ii)   Nil	2,224,286
d)	Aggregated information
	- Aggregated volume	2,267,500
	- Price	Nil
e)	Date of the transaction	2026-04-17
f)	Place of the transaction	XOFF - Outside of a Trading Venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Professor Sir Christopher Evans
2	Reason for the notification
a)	Position/status	Board Director / Chief Scientific Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	EDX Medical Group plc
b)	LEI	213800BZVJZTMCZ6DJ63
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of  £0.01 each
	Identification code	ISIN: GB00BNDMJS47
b)	Nature of the transaction	Granting of options over ordinary shares under the EDX Medical Group plc Enterprise Management Incentive Plan
c)	Price(s) and volume(s)
			Price	Volume
			Nil	1,500,000
d)	Aggregated information
	- Aggregated volume	1,500,000
	- Price	Nil
e)	Date of the transaction	2026-04-17
f)	Place of the transaction	XOFF - Outside of a Trading Venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jason Holt
2	Reason for the notification
a)	Position/status	Board Director / Non-Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	EDX Medical Group plc
b)	LEI	213800BZVJZTMCZ6DJ63
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of  £0.01 each
	Identification code	ISIN: GB00BNDMJS47
b)	Nature of the transaction	Granting of options over ordinary shares under the EDX Medical Group plc Non-Enterprise Management Incentive Plan
c)	Price(s) and volume(s)
			Price	Volume
			Nil	1,500,000
d)	Aggregated information
	- Aggregated volume	1,500,000
	- Price	Nil
e)	Date of the transaction	2026-04-17
f)	Place of the transaction	XOFF - Outside of a Trading Venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Professor Trevor Jones
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	EDX Medical Group plc
b)	LEI	213800BZVJZTMCZ6DJ63
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of  £0.01 each
	Identification code	ISIN: GB00BNDMJS47
b)	Nature of the transaction	Granting of options over ordinary shares under the EDX Medical Group plc Non-Enterprise Management Incentive Plan
c)	Price(s) and volume(s)
			Price	Volume
			Nil	1,500,000
d)	Aggregated information
	- Aggregated volume	1,500,000
	- Price	Nil
e)	Date of the transaction	2026-04-17
f)	Place of the transaction	XOFF - Outside of a Trading Venue

ENDS

For enquiries, please contact:

EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer)	[phone]
Canaccord Genuity Limited (Nominated Adviser and Broker)
Stuart Andrews	[phone]
Oberon Capital (Aquis Corporate Adviser and Broker
Nick Lovering	[phone]
Media House International
Ramsay Smith Gary McQueen	[phone] [e-mail] + 44 (0)7834 694609 [e-mail]
IFC Advisory (Investor Relations)
Graham Herring Tim Metcalfe	[phone]

Notes to Editors:

About EDX Medical Group plc

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com

 

END